Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

Summary

This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis

Timeline

Start

2020-01-13

Primary completion

2020-09-23

Completion

2020-09-25

Outcome

Met primary endpoint

registry analysis (superiority test); Roflumilast Foam 0.3% vs Vehicle Foam; p <0.0001; Odds Ratio (OR) 14.65 (95% CI 6.64 to 32.32); Cochran-Mantel-Haenszel NCT04128007 ↗

Drugs

Indications